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Summary We have investigated the incidence of Gorlin syndrome (GS) in patients with the childhood brain
tumour, medulloblastoma. One hundred and seventy-three consecutive cases of medulloblastoma in the
North-West Regional Health Authority between 1954 and 1989 (Manchester Regional Health Board before
1974) were studied. After review of case notes, X-rays and health surveys only 2/173 cases had evidence
supporting a diagnosis of GS. A further case at 50% risk of GS died of a brain tumour aged 4 years. The
incidence of GS in medulloblastoma is, therefore, probably between 1-2%. A population based study of GS
in the region started in 1983 was used to assess the incidence of medulloblastoma in GS, which was found to
be between 3-5%. This figure is lower than previous estimates, but this is the first population based study
undertaken. In view of the early age of onset in GS (mean 2 years) children presenting with medulloblastoma,
especially under 5 years, should be examined for signs of the syndrome. Those at high risk of developing
multiple invasive basal cell carcinomata will then be identified.
Gorlin or Naevoid Basal Cell Carcinoma syndrome was first
delineated in 1960 (Gorlin & Goltz). It is an autosomal
dominant condition characterised by the development of
multiple basal cell carcinomata and jaw cysts. Skeletal
anomalies are very common (Gorlin, 1987). Calcification of
the falx cerebi occurs early in life in 85% and bridging of the
sella turcica in 60-80% (normal 5% and 4%). Rib abnor-
malities, especially bifid rib is present in 60% and vertebral
anomalies in 40%. Short fourth metacarpal is present in
15-40%, but this is a less reliable sign due to its rather high
incidence (10%) in the normal population. Children with the
condition often have a birth weight and head circumference
above the 97th centile. There have been over 30 reports of
medulloblastoma in GS or their first degree relatives. Esti-
mates of its incidence in GS have been as high as 20% (Chan
& Little, 1983). Patients receiving craniospinal radiotherapy
after tumour diagnosis develop multiple invasive basal cell
carcinomata in the radiation field 6 months to 3 years after
treatment (Strong, 1977). Experience with one such case
(Evans et al., 1991) led us to undertake a population based
study to assess the incidences of medulloblastoma in GS and
GS in medulloblastoma.
Subjects and methods
All cases of childhood medulloblastoma on the Manchester
Children's Tumour Registry (MCTR) between 1 January
1954 and 31 December 1989 were studied. The MCTR is
population based and has a very high level of ascertainment
(Birch, 1988). Treatment for medulloblastoma is centralised
and virtually all regional cases attend the Christie Hospital
for radiotherapy and are followed up indefinitely. MCTR
case records are particularly extensive and are updated every
12 months. All pathology is reviewed by a panel of experts
and only those confirmed as medulloblastoma are recorded.
Where possible, hospital notes were reviewed in addition to
the MCTR notes. All relevant information was collated. All
X-ray reports on chest, skull and spine as well as birth
weight were recorded. All available X-rays were reviewed
with the diagnosis of GS in mind. Any reported skin or
dental problem and the results of post mortem examination
were also studied. Some of the cases had been included in
earlier epidemiological studies and their parents had been
interviewed to ascertain family history of neoplasms and also
any other family history such as illness and X-ray examina-
tions.
A population based study of GS was undertaken for the
North-West region in 1983 (Farndon, 1988). All dermato-
logical, oral surgery and plastic surgery departments were
approached for patients. As a result of this study and further
attempts to ascertain patients in the last year through a
regional GS register set up in March 1990, we have identified
73 living cases from 29 families. An extensive pedigree was
constructed on each family and in each case nearly all at risk
relatives were interviewed, examined and X-rayed. A family
history of tumours or early deaths was particularly sought.
Results
Medulloblastoma study
Birth weight could be identified in 83 cases mostly as a result
ofepidemiological surveys, results ofwhich were available on
53 of the first 79 cases and a total of 70/173. Average birth
weight was 3690 g ( + 0.51 s.d.) 5/83 cases had a birth weight
> +2 s.d.
CXR reports were available in 106 cases and were review-
ed in 50. The only significant abnormalities found were
multiple bifid ribs in the two identified cases ofGS. Although
a further case had rudimentary first ribs, full skeletal survey
was confirmed as being otherwise normal and the child had
developed no signs of GS 44 months after diagnosis. Skull
X-rays were reported in 132 of which 66 could be verified.
The two cases of GS showed gross expansion of the skull
vault, bridging of the sella turcica and gross lamellar falx
calcification by 10 years of age. No calcification was noted
on reports of other cases and no significant change seen on
those X-rays verified. In 63/73 cases we could review lateral
skull X-rays. Apart from the two with GS a further two had
bridging of the sella turcica. However they were both over 7
years at diagnosis, had no abnormalities on CXR and were
both alive at the time of the study with no other evidence of
GS. Spinal X-rays were available in 66 and checked in 47,
the only gross congenital abnormality was a sacral spina
bifida occulta in one case, there was no supporting evidence
for GS and she was 10 years old at diagnosis. Bone age
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X-rays were performed in many cases, these could be review-
ed in 47, none of which showed short 4th metacarpals. In
only 25/173 cases was there no radiological data and in only
six of the most recent 100 cases.
All records were particularly analysed for dermatological
problems. The two cases of GS both developed basal cell
carcinomata. Among the other cases, two had skin disease
which caused problems. One patient had a resistant seborr-
heic dermatitis on the scalp which had cleared completely at
the time of death 61 months after radiotherapy. Another
patient developed granulomas on the back which resolved
spontaneously, the skin is clear 13 years after treatment. A
total of 78 patients survived to 3 years after radiotherapy, an
interval during which they may be expected to have develop-
ed basal cell carcinomata (Strong, 1977).
Post mortem findings were available on 28 of the cases
that died. No evidence supporting a diagnosis of GS was
found in any of these. Both cases of GS had developed jaw
keratocysts in the second decade, but no other case could be
found. The first case presented aged 29 months and even-
tually died 30 years after his medulloblastoma having had
over 70 operations for basal cell carcinomata (Evans et al.,
1991). The second case was diagnosed aged 15 months and is
still alive 23 years after diagnosis. Both cases were mentally
retarded. Only 7/173 of the medulloblastoma patients had
insufficient data to reduce their risk of having GS. Their ages
were 74, 11, 7, 151, 177, 133 and 4 months, respectively.
Population basedstudy ofGS
A total of 29 families were identified and included 72 living
individuals with GS. This represents a prevalence of 1:56,000
for the population studied. By extrapolating the pedigrees
back to those alive in the period 1954 to 1989, we could find
at least 84 cases. In all but 3/72 living cases there was some
evidence of GS in one or other of their parents. The propor-
tion caused by new mutation of the GS gene in our study
population may be as low as 4.17%. Only two cases did not
live long enough to have medulloblastoma. The first died of
cardiac fibromata in the neonatal period and the second of
extreme prematurity. The two cases ofmedulloblastoma were
also ascertained by this population based study. A third
probable case of medulloblastoma occurred in a 4 year old
boy who died of a posterior fossa tumour found on CT scan.
He was at 50% risk of GS as his mother is a known case,
unfortunately he died preoperatively and post-mortem was
refused.
Literature review
There have been at least 37 reports of GS in association with
medulloblastoma. Gorlin et al. (1965) referred to three cases
he had heard of by personal communication. There were no
details of these cases and two other cases (Rayner et al.,
1977; Woolgar et al., 1987) who were noted to have died of
the disease and had relatives with GS, also had no further
details. The details of those surviving (Table I) and those
cases noted to have died from the disease (Table II) are
presented. Several cases have been reported twice (Neblett et
al., 1971; Anderson & Cook, 1966; Taylor et al., 1968). The
average age of onset in those surviving was 2.11 years. When
our two cases are added this gives an average age of diag-
nosis of 2.08 in 20 cases. Those who died usually only had
that date given, so the average age for death in these individ-
uals was 3.46 years. Sixteen/18 survivors were noted to
develop basal cell carcinomas in the radiation field within 9
years. The two remaining cases were only 1 and 4 years
post-radiotherapy at the time the articles were written.
Discussion
The association between GS and medulloblastoma is well
established by the large number of reports of the two rela-
TableI MedulloblastomacasesinGS,ageatpresentation andinterval
to development of basal cell carcinoma
Interval to development
Paper Case Age ofbasal cell carcinoma
Herzberg & Wiskemann, 1963 1 2 months <5 months
Cawson & Kerr, 1964 1 12 1 year
Hermans et al., 1965 1 48 2 years
Graham et al., 1968 1 10 <9 years
Neblett et al., 1971 1 15 <8 years
Moynahan, 1973 1 12 <9 years
Strong, 1977 1 18 <3 years
Heimler et al., 1978 1 29 <3 years
Cutler et al., 1979 1 12 1 year
2 84 none at 4 years
Hawkins et al., 1979 1 30 5 years
Southwick & Schwartz, 1979 1 24 2 years
Lindeberg et al., 1982 1 23 <5 years
Naguib et al., 1982 1 36 4 years
Kraemer et al., 1984 1 18 5.5 years
Balsa et al., 1985 1 48 none at I year
Woolgar et al., 1987 1 24 <7 years
Chevrant et al., 1988 1 10 <7 years
Table II Medulloblastoma in GS cases, or in first or second degree
relatives of GS cases and age at death
Paper Case Age at death (months)
Meerkotter & Shear, 1964 1 24
Telle, 1965 1 12
Kennedy & Abbot, 1968 1 24
Taylor et al., 1968 1 60
Jackson & Gardere, 1971 1 72
2 24
Neblett et al., 1971 1 48
2 30
Amin, 1975 1 48
Ramsden & Barrett, 1978 1 12
Leppard, 1983 1 108
2 72
Potaznik & Steinhertz, 1984 1 18
tively rare conditions coexisting. Estimates of the frequency
of medulloblastoma in GS have been as high as 20% (Chan
& Little, 1983). There has been no population based study,
until now, to estimate the true figure. Difficulties in coming
to an accurate estimate have been due to inability to diag-
nose GS in those patients who have died of tumour, before
they would have manifested features of GS. We have found
sufficient data in at least 80% of our cases to make a
diagnosis of GS unlikely. At least 90% of individuals with
GS manifest a radiologically detectable abnormality. The
only failing of our available radiological data is that those
patients who died under 10 years may not yet have developed
calcification on skull X-ray. We would expect those with GS
to develop tumour at an average age of 2 years. However it
is likely that the gene would manifest itself in at least one
other way and indications are that those with GS run a more
benign course and are more likely to survive (Gorlin, 1987).
Those surviving at least 3 years are likely to have basal cell
carcinomas in the radiation field. Although previous papers
refer to this complication as late as 9 years after therapy they
do not mention when they first occurred.
Other indicators such as high birthweight were not useful
in identifying cases. Although the average birthweight was
high 3690 g ( + 0.51 s.d.) and more cases than expected had a
weight above the 97th centile (4/71), the extreme cases could
be excluded on other grounds such as age of onset.
The medulloblastoma series is particularly strong in that it
is supported by a population based study of GS which is
likely to have a high level of ascertainment. The two definite
and one likely case were all also identified by this means.
Any cases of medulloblastoma which did have GS, would
have to be from families we have not identified, or occur asGORLIN SYNDROME AND MEDULLOBLASTOMA 961
new mutations. Both of these are unlikely due to our high
ascertainment and low mutation rates. Only 3/173 cases had
no real data and occurred at ages compatible with GS. The
incidence ofmedulloblastoma in our GS population was 3/84
(3.6%). In view of the high level of ascertainment achieved
by the MCTR the third case could be added to the statistics
without much adjustment. This would give an incidence of
GS in medulloblastoma of 1-2%.
We have presented a population based series of medullo-
blastoma and GS which has given the first accurate estimate
of their associations. It is important to identify those individ-
uals with medulloblastoma who have GS, as it may alter the
way in which radiotherapy is administered, to diminish any
unnecessary skin exposure. Suspicion should be higher the
younger the patient. Although only 1-2% had GS in the
whole series this represented 4.5% of those under 5 years and
5% of those under 3 years. A diagnosis of GS will alert the
clinican to the almost inevitable crop of basal cell carcin-
omata, which can then be managed optimally. Other compli-
cations, such as jaw cysts, could be anticipated by regular
dental screening (orthopantograms). It may also result in
further family members with GS being identified. Finally,
those families known to have GS should have any new issue
checked for features of the condition. Those at risk should
have regular neurological checks (6 monthly for first 3 years
then annually until 7 years) and where any doubt exists a
brain scan should be arranged.
The Manchester Childrens Tumour Registry is supported by the
Cancer Research Campaign. Dr J.M. Birch is a CRC senior research
fellow.
References
AMIN, R. (1975). Basal cell naevus syndrome. Br. J. Radiol., 48, 402.
ANDERSON, D.E. & COOK, W.A. (1966). Jaw cysts and basal cell
nevus syndrome. J. Oral Surg., 24, 15.
BALSA, R.E., INGRATTA, S.M., GALLIANO, F.E., RAFFAELI, C.A.,
DRUT, R. & VESTFRID, M. (1985). Basal cell nevus syndrome.
Presentation of two cases, one associated with medulloblastoma.
Med. Cutan. Ibero. Lat. Am., 13, 5.
BIRCH, J.M. (1988). Manchester children's tumour registry 1954-
1970 and 1971-1983. In International Incidence of Childhood
Cancer, Parkin, D.M., Stiller, C.A., Draper, G.J., Bieber, C.A.,
Terracini, B. & Young, J.A. (eds), p. 299. IARC Scientific Pub-
lication: Lyon.
CAWSON, R.A. & KERR, G.A. (1964). The syndrome of jaw cysts,
basal cell tumours and skeletal anomalies. Proc. R. Soc. Med., 57,
799.
CHAN, G.L. & LITTLE, J.B. (1983). Cultured diploid fibroblasts from
patients with the nevoid basal cell carcinoma syndrome are
hypersensitive to ionising radiation. Am. J. Pathol., 111, 50.
CHEVRANT-BRETON, J., BOUSSER, A.M., AUNAC-RAOUL, M., FAI-
VRE, J., COLLAS, P. & LANCIEN, G. (1988). Naevomatose baso-
cellulaire et medulloblastome. Ann. Dermatol. Venereol., 115,
1115.
CUTLER, T.P., HOLDEN, C.A. & MACDONALD, D.M. (1979). Multiple
naevoid basal cell carcinoma syndrome (Gorlin's syndrome). Clin.
Exp. Dermatol., 4, 373.
EVANS, D.G.R., BIRCH, J.M. & ORTON, C.I. (1991). Brain tumours
and the occurrence of severe invasive basal cell carcinomata in
first degree relatives with Gorlin syndrome. Br. J. Neurosurg. (in
press).
FARNDON, P. (1988). The natural history of Gorlin (naevoid basal
cell carcinoma) syndrome. J. Med. Genet., 25, 638.
GORLIN, R.J. (1987). Nevoid basal-cell carcinoma syndrome. Medi-
cine, 66, 98.
GORLIN, R.J., VICKERS, R.A., KELLIN, E. & WILLIAMSON, J.J.
(1965). The multiple basal cell nevi syndrome. An analysis of a
syndrome consisting of multiple basal cell carcinoma, jaw cysts,
skeletal anomalies, medulloblastoma and hyporesponsiveness to
parathormone. Cancer, 18, 89.
GRAHAM, J.K., MCJIMPSEY, B.A. & HARDIN, J.C. (1968). Nevoid
basal cell carcinoma syndrome. Arch. Otolaryngol., 87, 72.
HAWKINS, J.C., HOFFMAN, H.J. & BECKER, L.E. (1979). Multiple
nevoid basal cell carcinoma syndrome (Gorlin's syndrome). Possi-
ble confusion with metastatic medulloblastoma. J. Neurosurg., 50,
100.
HEIMLER, A., FRIEDMAN, E. & ROSENTHAL, A.D. (1978). Naevoid
basal cell carcinoma syndrome and Charcot-Marie-Tooth disease.
J. Med. Genet., 15, 288.
HERMANS, E.H., GROSFELD, J.C.M. & SPAAS, J.A.J. (1965). The fifth
phacomatosis. Dermatologica, 130, 446.
HERZBERG, J.J. & WISKEMANN, A. (1963). Die funfte phakomatose
bazalcellnaevus mit familiarer belastung und medulloblastom.
Dermatologica, 126, 106.,
JACKSON, R. & GARDERE, S. (1971). Nevoid basal cell carcinoma
syndrome. Canad. Med. Assoc. J., 105, 850.
KENNEDY, J.W. & ABBOT, P.L. (1968). Nevoid basal cell carcinoma
syndrome. Report of two cases. Oral. Surg., 26, 406.
KRAEMER, B.B., SILVA, E.G. & SNEIGE, N. (1984). Fibrosarcoma of
ovary: a new component in the nevoid basal cell carcinoma
syndrome. Am. J. Surg. Pathol., 8, 231.
LEPPARD, B.J. (1983). Skin cysts in the basal cell naevus syndrome.
Clin. Exp. Dermatol., 8, 603.
LINDEBERG, H., HALABURT, H. & LARSEN, P.O. (1982). The nae-
void basal cell carcinoma syndrome. J. Max. Fac. Surg., 10, 246.
MEERKOTTER, V.A. & SHEAR, M. (1964). Multiple primordial cysts.
Oral. Surg., 18, 498.
MOYNHAN, E.J. (1973). Multiple nevoid basal cell naevus syndrome
-Successful treatment of basal cell tumours with 5-fluorouracil.
Proc. R. Soc. Med., 66, 627.
NAGUIB, M.G., SUNG, J.H., ERICKSON, D.L., GOLD, L.H.A. & SELJE-
SKOG, E.L. (1982). Central nervous system involvement in the
nevoid basal cell carcinoma syndrome. Case report and review of
the literature. Neurosurg., 11, 52.
NEBLETT, C.R., WALTZ, T.A. & ANDERSON, D.E. (1971). Neuro-
logical involvement in the nevoid basal cell carcinoma syndrome.
J. Neurosurg., 35, 577.
POTAZNIK, D. & STEINHERZ, P. (1984). Multiple nevoid basal cell
carcinoma syndrome and Hodgkin's disease. Cancer, 53, 2713.
RAMSDEN, R.T. & BARRETT, A. (1978). Gorlin's syndrome. J.
Laryngol. Otol., 89, 615.
RAYNER, C.R.W., TOWERS, J.F. & WILSON, J.S.P. (1977). What is
Gorlin's syndrome? The diagnosis and management of basal cell
naevus syndrome based on a study of thirty seven patients. Br. J.
Plast. Surg., 30, 62.
SOUTHWICK, G.J. & SCHWARTZ, R.A. (1979). The basal cell nevus
syndrome. Disasters occurring among a series of 36 patients.
Cancer, 44, 2294.
STRONG, L.C. (1977). Genetic and environmental interactions. Can-
cer, 40, 1861.
TAYLOR, W.B., ANDERSON, D.E., HOWELL, J.B. & THURSTON, J.S.
(1968). The nevoid basal cell carcinoma syndrome. Arch. Derma-
tol., 98, 612.
TELLE, B. (1965). Multiple basaliome bei einem jungen. Mann. Derm.
Wschr., 151, 1425.
WOOLGAR, J.A., RIPPIN, J.W., TAYLOR, M. & BROWNE, R.M. (1987).
Basal cell naevus syndrome. Br. J. Hosp. Med., Oct, 344.